2,3,5-triphenyl-2H-tetrazolium chloride monohydrate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2,3,5-triphenyl-2H-tetrazolium chloride monohydrate
• 英文别名: 2,3,5-triphenyltetrazolium chloride monohydrate；TTC hydrate；RT water；2,3,5-triphenyltetrazol-2-ium;chloride;hydrate
• 化学式: C₁₉H₁₅N₄*Cl*H₂O
• 分子量: 352.823
• InChiKey: LJVSLFRHFMUIDK-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -0.61
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  35.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,3,5-triphenyl-2H-tetrazolium chloride monohydrate 、 五氯化磷 以 neat (no solvent) 为溶剂， 以25.6%的产率得到2,3,5-triphenyltetrazolium dichlorophosphate
  参考文献：
  名称：

  Formation and Crystal Structure of 2,3,5-Triphenyltetrazolium Hexachlorophosphate and Dichlorophosphate(V), [TPT]⁺[PCl₆]^– and [TPT]⁺[PO₂Cl₂]^–

  摘要：

  2,3,5-三苯基四唑六氯磷酸盐，[C₁₉H₁₅N₄]⁺[PCl₆]⁻，[TPT]⁺[PCl₆]⁻（1），以及2,3,5-三苯基四唑二氯磷酸盐（V），[C₁₉H₁₅N₄]⁺[PO₂Cl₂]⁻，[TPT]⁺[PO₂Cl₂]⁻（2），通过无水2,3,5-三苯基四唑氯化物，[TPT]⁺Cl⁻，和2,3,5-三苯基四唑氯化物一水合物[TPT]⁺Cl− ・H₂O，与干燥的乙腈中的PCl₅反应合成，并通过单晶X射线衍射分析确定其晶体结构。在这两种化合物中，[TPT]⁺阳离子在相邻分子的苯环之间呈面对面堆叠的取向，这是由分子间π ・ ・ ・π相互作用引起的。化合物1的晶体结构由2,3,5-三苯基四唑阳离子和六氯磷酸盐阴离子层组成。在化合物2中，四面体[PO₂Cl₂]⁻阴离子具有近似C_2v对称性，P-O键长从1.454到1.463 Å，P-Cl键长从2.038到2.050 Å。记录了化合物1的拉曼光谱，并提出了[PCl₆]⁻拉曼模式的归属。

  DOI：

  10.1515/znb-2009-0901

文献信息

• SPAK KINASE INHIBITORS AS NEUROPROTECTIVE AGENTS
  申请人：United States Government as represented by the Department of Veterans Affairs

  公开号：US20200102266A1

  公开（公告）日：2020-04-02

  The present disclosure is concerned with N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)benzamide compounds that are capable of inhibiting SPAK kinase function, methods of treating hypoxic brain injuries due to, for example, ischemic stroke. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本公开涉及能够抑制SPAK激酶功能的N-(5-氯-4-((4-氯苯基)(氰基)甲基)-2-甲基苯基)苯甲酰胺化合物，以及治疗缺氧性脑损伤（例如缺血性卒中）的方法。本摘要旨在作为在特定领域搜索的扫描工具，不旨在限制本发明。
• Synthesis, Crystal Structure and Vibrational Spectrum of 2,3,5-Triphenyltetrazolium Hexachloridoniobate(V) and Oxidotetrachloridoniobate(V) Acetonitrile, [TPT][NbCl₆] and [TPT][NbOCl₄(CH₃CN)]
  作者：Mimoza Gjikaj、Tao Xie、Wolfgang Brockner

  DOI：10.1002/zaac.200900174

  日期：2009.11

  Single crystals of 2,3,5-triphenyltetrazolium hexachloroniobate(V), [TPT] [NbCl6], (1) and of 2,3,5-triphenyltetrazolium oxotetrachloroniobate(V), [TPT] [NbOCl4(CH3CN)], (2) could be obtained and their crystal structures determined. The yellow compound 1 crystallizes in the monoclinic space group P21/c (C2h5, no. 14) with a = 1321.6(3), b = 1080.7(2), c = 1740.2(4) pm, β = 111.54(2)°, and Z = 4. Its

  2,3,5-三苯基四唑鎓六氯铌酸盐 (V), [TPT] [NbCl6], (1) 和 2,3,5-三苯基四唑鎓氧四氯铌酸盐 (V), [TPT] [NbOCl4(CH3CN)], ( 2) 可以得到并确定它们的晶体结构。黄色化合物 1 在单斜空间群 P21/c (C2h5, no. 14) 中结晶，a = 1321.6(3), b = 1080.7(2), c = 1740.2(4) pm, β = 111.54(2)° ，Z = 4。它的结构与最近表征的 [TPT] [SbCl6] 的结构同型，由 [TPT]+ 阳离子和八面体 [NbCl6]- 阴离子构成。淡黄色化合物 2 在正交空间群 Pbcm (D2h11, no. 57) 中结晶，a = 1574.4(1), b = 1047.7(1), c = 1723.4(1) pm，Z = 4。 离子化合物包含 [TPT]+ 阳离子和 [NbOCl4(CH3CN)]-
• Acidic polycyclic ether antibiotic having anticoccidial and growth promotant activity
  申请人：PFIZER INC.

  公开号：EP0328303A2

  公开（公告）日：1989-08-16

  An acidic polycyclic ether antibiotic, having structure established by X-ray crystallography, is formed by fermentation of a novel microorganism, Actinomadura sp. ATCC 53708. This novel antibiotic is useful as an anticoccidial in chickens, in the prevention or treatment of swine dysentery, and as a growth promotant in cattle and swine.

  新型微生物 Actinomadura sp. ATCC 53708 通过发酵形成了一种酸性多环醚抗生素，其结构已通过 X 射线晶体学确定。这种新型抗生素可用作鸡的抗球虫药、预防或治疗猪白痢，以及牛和猪的生长促进剂。
• ARTEMISININ AND ITS DERIVATIVES FOR USE IN THE TREATMENT OF MYOCARDIAL INFARCTION OR CORONARY HEART DISEASE
  申请人：Queen Mary University of London

  公开号：EP3269371A1

  公开（公告）日：2018-01-17

  The present invention relates to the treatment of trauma haemorrhage or trauma haemorrhage-induced organ injury and associated disorders (in particular stoke, burns and brain injury) using the anti-malarial compound artemisinin and its derivatives. The present invention also relates to the treatment of myocardial infarction and coronary heart disease (and associated disorders) using the anti-malarial compound artemisinin and its derivatives. The present invention also relates to the use of artemisinin and its derivatives in coronary artery bypass surgery, heart transplantation, and diseases associated with ischaemia-reperfusion.

  本发明涉及使用抗疟化合物青蒿素及其衍生物治疗创伤出血或创伤出血引起的器官损伤及相关疾病（特别是昏迷、烧伤和脑损伤）。本发明还涉及使用抗疟疾化合物青蒿素及其衍生物治疗心肌梗塞和冠心病（及相关疾病）。本发明还涉及青蒿素及其衍生物在冠状动脉搭桥手术、心脏移植和缺血再灌注相关疾病中的应用。
• Combination therapy using immunoglobulin and C1-Inhibitor
  申请人：Basta Milan

  公开号：US10471142B2

  公开（公告）日：2019-11-12

  Methods are disclosed for treating cerebral ischemia using a combination of C1-INH and immunoglobulin, such as human plasma derived immunoglobulin (IVIG).

  公开了使用 C1-INH 和免疫球蛋白（如人血浆衍生免疫球蛋白（IVIG））组合治疗脑缺血的方法。